Literature DB >> 3932489

Safety of intravenous immunoglobulin treatment.

H I Atrah, R J Crawford, B C Dow, R Mitchell.   

Abstract

In a prospective clinical and biochemical study of 16 patients treated with high doses of an immunoglobulin product that had been modified for intravenous use by mild pepsin treatment at pH 4 no evidence of hepatitis could be found. This contrasts with recent reports that intravenous immunoglobulin products can apparently transmit non-A, non-B hepatitis.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3932489      PMCID： PMC499468          DOI： 10.1136/jcp.38.10.1192

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


  8 in total

1.  Non-A, non-B hepatitis from intravenous immunoglobulin.

Authors:  A G Welch; B Cuthbertson; R V McIntosh; P R Foster
Journal:  Lancet       Date:  1983-11-19       Impact factor: 79.321

2.  Non-A, non-B hepatitis from intravenous immunoglobulin.

Authors:  R S Lane
Journal:  Lancet       Date:  1983-10-22       Impact factor: 79.321

3.  A West African epilepsy focus.

Authors:  C Gerrits
Journal:  Lancet       Date:  1983-02-12       Impact factor: 79.321

4.  Non-A, non-B hepatitis and intravenous immunoglobulin.

Authors: 
Journal:  Lancet       Date:  1985-02-16       Impact factor: 79.321

5.  Non-A, non-B hepatitis markers in the west of Scotland.

Authors:  B C Dow; E A Follett; R Mitchell
Journal:  Med Lab Sci       Date:  1981-10

6.  Non-A non-B hepatitis after transfusion of factor VIII in infrequently treated patients.

Authors:  M L Fletcher; J M Trowell; J Craske; K Pavier; C R Rizza
Journal:  Br Med J (Clin Res Ed)       Date:  1983-12-10

Review 7.  The use and mechanism of action of intravenous immunoglobulin in the treatment of immune haematologic disease.

Authors:  J B Bussel; M W Hilgartner
Journal:  Br J Haematol       Date:  1984-01       Impact factor: 6.998

8.  Non-A, non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin.

Authors:  A M Lever; A D Webster; D Brown; H C Thomas
Journal:  Lancet       Date:  1984-11-10       Impact factor: 79.321
  8 in total
  1 in total

1.  Use of intravenous immunoglobulin in severe refractory idiopathic immune thrombocytopenia.

Authors:  D Maharaj; J H McKillop
Journal:  J R Soc Med       Date:  1987-10       Impact factor: 18.000
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.